← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	2,350	0	0%	$238B
2	2 Pfizer PFE $166B	2,050	-25	-1%	$141B
3	3 Merck MRK $364B	1,926	-16	-0.8%	$130B
4	4 AbbVie ABBV $501B	1,763	+36	+2%	$80.1B
5	5 Amgen AMGN $230B	1,596	-5	-0.3%	$99.4B
6	6 Bristol-Myers Squibb BMY $121B	1,595	-3	-0.2%	$63.9B
7	7 Gilead Sciences GILD $190B	1,521	-5	-0.3%	$69.4B
8	8 Novartis NVS $279B	921	+11	+1%	$21.7B
9	9 GSK GSK $95.9B	780	-7	-0.9%	$9.91B
10	10 Regeneron Pharmaceuticals REGN $80.1B	604	+25	+4%	$35.9B
11	11 Incyte INCY $22.6B	493	-16	-3%	$23.9B
12	12 AstraZeneca AZN $251B	467	+5	+1%	$12.3B
13	13 Jazz Pharmaceuticals JAZZ $13.6B	319	+13	+4%	$8.31B
14	SGEN 14 DELISTED Seagen Inc. Common Stock SGEN	301	+2	+0.7%	$7.29B
15	CLVS 15 DELISTED Clovis Oncology, Inc. CLVS	271	+42	+18%	$4.57B
16	16 DELISTED Exact Sciences EXAS	266	+41	+18%	$3.65B
17	17 Exelixis EXEL $15.1B	249	+20	+9%	$5.79B
18	18 Myriad Genetics MYGN $397M	239	+6	+3%	$2.12B
19	19 Opko Health OPK $1.02B	232	-13	-5%	$855M
20	20 Qiagen QGEN $9.41B	211	+28	+15%	$4.77B
21	21 DELISTED Assertio ASRT	177	-16	-8%	$625M
22	22 DELISTED Eagle Pharmaceuticals, Inc. EGRX	175	+28	+19%	$1.21B
23	23 Precigen PGEN $2.64B	172	+18	+12%	$2.41B
24	24 Halozyme HALO $13.3B	167	+7	+4%	$1.56B
25	25 DELISTED Immunogen Inc IMGN	157	+22	+16%	$542M